Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 1/2009

01-03-2009 | Original Article

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

Authors: Sudarshan K. Vijay, Manish Mishra, Hemant Kumar, K. Tripathi

Published in: Acta Diabetologica | Issue 1/2009

Login to get access

Abstract

The purpose of this study was to assess the effects of PPAR-γ agonists (pioglitazone and rosiglitazone) on mediators of endothelial dysfunction and markers of angiogenesis in patients with type-2 diabetes. Pioglitazone group showed favorable reductions in serum total cholesterol, triglycerides, LDL cholesterol, VLDL cholesterol and increase in HDL cholesterol as compared to rosiglitazone group, after 16 weeks of treatment and also with control group. There was significant reduction of CRP level in pioglitazone and rosiglitazone group. The level of serum TNF-α decreased significantly in pioglitazone and mildly decreased in rosiglitazone group. The level of VEGF, IL-8 and Angiogenin were increased in pioglitazone than rosiglitazone group. There were no significant changes observed in the serum angiogenin and IL-8 levels in the control group. Pioglitazone and rosiglitazone therapy in type-2 diabetes subjects have additional benefits of reducing mediators of endothelial dysfunction. Increase in angiogenesis markers in patients receiving pioglitazone could have variable effects in diabetic nephropathy and retinopathy as there may be increased vascular neogenesis. Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines.
Literature
1.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriocler Thromb Vasc Biol 19:972–978
2.
Verma S, Buchanan MR, Anderson TJ (2003) Endothelial function testing as a biomarker of vascular disease. Circulation 108:2054–2059PubMedCrossRef
3.
Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:2058–2067PubMedCrossRef
4.
Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA (2002) Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:1890–1896PubMedCrossRef
5.
Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S (2003) C-reactive protein upregulates angiotensin type-1 receptors in vascular smooth muscle. Circulation 107:1783–1790PubMedCrossRef
6.
Rask-Madsen C, Domínguez H, Ihlemann N, Hermann T, Køber L, Torp-Pedersen C (2003) Tumor necrosis factor-alpha inhibits insulin’s stimulating effect on glucose uptake and endothelial dependent vasodilatation in humans. Circulation 108:1815–1821PubMedCrossRef
7.
Peraldi P, Spiegelman B (1998) TNF-alpha and Insulin resistance: Summary and future prospects. Mol Cell Biochem 182:169–175PubMedCrossRef
8.
McNeill KL, Fontana L, Russell-Jones DL, Rajman I, Ritter JM, Chowienczyk PJ (2000) Inhibitory effects of low density lipoproteins from men with type-2 diabetes on endothelium dependent relaxation. J Am Coll Cardiol 35:1622–1627PubMedCrossRef
9.
Ginsberg HN (1991) Lipoprotein physiology in nondiabetic and diabetic status: relationship to atherogenesis. Diabetes Care 14:839–855PubMedCrossRef
10.
Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR, Gardiner TA (2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54:785–794PubMedCrossRef
11.
Currie CJ, Morgan CL, Peters JR (1998) The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 21:42–48PubMedCrossRef
12.
Abaci A, Oğuzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, Ergin A (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239–2242PubMed
13.
Favard C, Ortega N, Bayard F, Plouet J (1996) Vascular endothelial growth factor and retinal neovascularisation : a new therapeutic approach for diabetic retinopathy. Diabetes Metab 22:368–373
14.
Sharma NK, Gardiner TA, Archer DB (1985) A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Opthalmol 100:51–60
15.
Mizutani M, Kern TS, Lorenzi M (1996) Accelerated death of retinal microvasculature cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883–2890PubMedCrossRef
16.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidediones is a high affinity ligand for perroxisome proliferators activated receptor gamma. J Biol Chem 270:12953–12956PubMedCrossRef
17.
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B (2002) Pleiotropic actions of peroxisome proliferators activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717–726PubMedCrossRef
18.
Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators (2005) A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type-2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554PubMedCrossRef
19.
Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24:378–396PubMedCrossRef
20.
Khan MA, St Peter JV, Xue JL (2002) A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708–711PubMedCrossRef
21.
Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704–711PubMedCrossRef
22.
Cabrero A, Cubero M, Llaverías G, Jové M, Planavila A, Alegret M, Sánchez R, Laguna JC, Carrera MV (2003) Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52:652–657PubMedCrossRef
23.
Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843PubMedCrossRef
24.
Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL (1995) TNF-alpha mediates recruitment of neutrophils and Eosinophils during airway inflammation. J Immunol 154:5411–5417PubMed
25.
Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT (2004) Effects of rosiglitazone on endothelial function, c-reactive protein and components of the metabolic syndrome in non diabetic patients with the metabolic syndrome. Am J Cardiol 93:362–365PubMedCrossRef
26.
Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 39:82–86
27.
Peraldi P, Xu M, Spiegelman BM (1997) Thiazolidinediones block tumour necrosis factor-alpha- induced inhibition of insulin signalling. J Clin Invest 100:1863–1869PubMedCrossRef
28.
Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A (2000) Vascular endothelial growth factor in children, adolescents and young adults with type-1 diabetes mellitus: relation to glycemic control and microvascular complications. Diabet Med 17:650–656PubMedCrossRef
29.
Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–1312PubMedCrossRef
30.
Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM (1998) Activatots of nuclear receptor PPAR-γ enhance colon polyp formation. Nat Med 4:1058–1061PubMedCrossRef
31.
Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J (1998) Activation of peroxisome proliferator activated receptor-γ promotes the development of colon tumors in C57BL/6 J-APC Min/t mice. Nat Med 4:1053–1057PubMedCrossRef
32.
Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y (2000) Peroxisone proliferator activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biopsy Res Comm 271:571–574CrossRef
33.
Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T (2001) The oral insulin sensitizer, thiazolidinedione increases plasma vascular endothelial growth level in type 2 diabetic patients. Diabetes Care 24:953–954PubMedCrossRef
34.
Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3–L1 adipocytes. Diabetes 50:1166–1170PubMedCrossRef
Metadata
Title
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes
Authors
Sudarshan K. Vijay
Manish Mishra
Hemant Kumar
K. Tripathi
Publication date
01-03-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0054-7

Other articles of this Issue 1/2009

Acta Diabetologica 1/2009 Go to the issue

Original Article

Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals

Original Article

Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control

Short Communication

Pioglitazone reduces monocyte activation in type 2 diabetes

Original Article

A single test procedure to diagnose gestational diabetes mellitus

Review Article

The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?

Original Article

Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits